Data / Drug companies / Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA: 338 products in the FDA NDC directory, labeler code 68462
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Glenmark Pharmaceuticals Inc., USA (labeler code 68462) lists 338 products in the FDA National Drug Code Directory, covering 134 finished drugs by generic name. By type: 338 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 12, 2026.
The request: Watch Glenmark Pharmaceuticals Inc., USA (FDA labeler code 68462): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68462
- Products in commercial distribution
- 338
- Packages
- 688
- Finished drugs by generic name
- 134
- Prescription products
- 338
- Over the counter products
- 0
- Controlled substance products
- Schedule II 5, Schedule IV 3, Schedule V 6
- Flagged as original packager
- 305 of 305 products that carry the flag
- Started marketing in the last 12 months
- 32
- Products with a marketing end date set
- 2
- Earliest marketing start
- August 1, 1999
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 333 | 98.5% |
| Authorized generics (NDA) | 4 | 1.2% |
| New drug applications (NDA) | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 338 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 80 | 23.7% |
| Tablet | 64 | 18.9% |
| Capsule | 36 | 10.7% |
| Injection, solution | 26 | 7.7% |
| Kit | 19 | 5.6% |
| Tablet, film coated, extended release | 16 | 4.7% |
| Capsule, extended release | 12 | 3.6% |
| Injection, powder, lyophilized, for solution | 11 | 3.3% |
| Ointment | 10 | 3% |
| Injection | 8 | 2.4% |
| Cream | 8 | 2.4% |
| Gel | 8 | 2.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Vancomycin Hydrochloride | 68462-958 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 12, 2026 |
| Vancomycin Hydrochloride | 68462-957 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 12, 2026 |
| Epinephrine | 68462-762 | Injection | Generic drugs (ANDA) | September 22, 2026 |
| Fluticasone Propionate | 68462-918 | Spray, metered | Generic drugs (ANDA) | August 18, 2026 |
| Sugammadex | 68462-696 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Sugammadex | 68462-695 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Nintedanib | 68462-803 | Capsule | Generic drugs (ANDA) | July 9, 2026 |
| Nintedanib | 68462-802 | Capsule | Generic drugs (ANDA) | July 9, 2026 |
| Calcium Gluconate | 68462-791 | Injection, solution | Generic drugs (ANDA) | May 4, 2026 |
| Calcium Gluconate | 68462-790 | Injection, solution | Generic drugs (ANDA) | May 4, 2026 |
| Calcium Gluconate | 68462-789 | Injection, solution | Generic drugs (ANDA) | May 4, 2026 |
| Vancomycin Hydrochloride | 68462-956 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 12, 2026 |
| Vancomycin Hydrochloride | 68462-955 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 12, 2026 |
| Progesterone vaginal inserts | 68462-175 | Insert | Generic drugs (ANDA) | April 8, 2026 |
| Fluticasone propionate | 68462-937 | Aerosol, metered | Generic drugs (ANDA) | March 24, 2026 |
| Milnacipran Hydrochloride | 68462-766 | Tablet, film coated | Authorized generics (NDA) | March 19, 2026 |
| Milnacipran Hydrochloride | 68462-765 | Tablet, film coated | Authorized generics (NDA) | March 19, 2026 |
| Milnacipran Hydrochloride | 68462-764 | Tablet, film coated | Authorized generics (NDA) | March 19, 2026 |
| Milnacipran Hydrochloride | 68462-763 | Tablet, film coated | Authorized generics (NDA) | March 19, 2026 |
| Lacosamide | 68462-697 | Injection, solution | Generic drugs (ANDA) | March 16, 2026 |
| Potassium phosphates | 68462-788 | Injection, solution, concentrate | Generic drugs (ANDA) | March 12, 2026 |
| Potassium phosphates | 68462-787 | Injection, solution, concentrate | Generic drugs (ANDA) | March 12, 2026 |
| Potassium phosphates | 68462-786 | Injection, solution, concentrate | Generic drugs (ANDA) | March 12, 2026 |
| Olanzapine | 68462-952 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 5, 2026 |
| Sodium phosphates | 68462-730 | Injection, solution | Generic drugs (ANDA) | February 23, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.